Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suven Life Sciences has published its audited financial results for the quarter and year ended March 31, 2026. The company reported very low revenues of Rs 152.01 lakhs for Q4 FY26 and Rs 711.47 lakhs for the full year. Despite modest revenue, the company posted significant losses - standalone net loss of Rs 1,116.73 lakhs for Q4 and Rs 5,486.28 lakhs for FY26. On a consolidated basis, losses were much steeper at Rs 4,559.55 lakhs for Q4 and a massive Rs 27,634.41 lakhs for the full year, indicating substantial losses in subsidiary operations. EPS for consolidated FY26 was Rs 12.13 per share (annualized), deeply negative. The results appeared in Andhra Prabha and Business Standard on May 14, 2026.
The company is reporting severe losses with very low revenues, indicating significant operational or financial distress. The large gap between standalone and consolidated losses suggests issues in subsidiaries. This is highly negative for shareholders and could put downward pressure on the stock.